In January through June 2011, Antibiotice reported a net profit of RON23.14 million.
The pharmaceuticals company said total sales increased 7.3% to RON148.6 million in the first six months, from RON138.5 million in the year-earlier period.
Overall revenue rose 1.4% on the year to RON166.26 million, while total costs inched up to RON136.6 million, from RON135.7 million in the first half of 2011.
The company’s majority holder is Romania’s Health Ministry, with a 53% stake, while investment fund SIF Oltenia (SIF5.RO) holds a 10% stake.
Antibiotice is the second-largest nystatin maker in the world, with a 35% market share, according to company information.
On the Bucharest market Wednesday, Antibiotice closed roughly flat on the day at RON0.3549 a share. (EUR1=RON4.5362)